Combination Therapies Could be the Future of Cancer Treatment, Suggests GBI Research

10 Aug 2012 • by Natalie Aster

In the on-going battle against cancer, the medical community is looking to promising multi-targeted therapies for more effective and enduring treatments. There is a wave of combination therapies in late stage development that have the potential to revolutionize long-term oncological treatment by addressing the complexities of cancer growth. In Silico methods (the use of computer simulations) have been instrumental in the generation of biological and chemical data on ligands and targets. These same methods are now being employed to identify and design multi-target compounds, facilitated by the wealth of bioactivity information advanced computer simulations provide.

According to the GBI Research's new report, "Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise", lung cancer treatments represent the greatest share of the Phase III combination therapy development pool with 16%. This relatively high percentage is not surprising considering the disease's growing prevalence around the world due to an increase in tobacco consumption in emerging economies such as China. The second and third most populous combination therapies in Phase III were breast cancer and colorectal cancer, with 13.4% and 8.5%, respectively. There are, however, regulatory problems regarding the co-development of novel drugs. The primary concern is that this process will inevitably provide less information about the safety and effectiveness of these agents than if they were developed and tested individually. The FDA has drafted guidance and recommendations on how combination therapies should be processed, including a proposal that drugs should only be developed in combination when there is a compelling biological rationale for the use of the combination, or where the drugs cannot be developed individually (if this were lead to drug resistance, for example). Combinations also need to be shown in preliminary clinical studies to provide greater-than-additive activity or a more durable response compared to using the agents alone.

The report "Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise" provides an overview of the discovery and development of therapeutic drug combinations and multi-target drugs for oncology.

Report Details:

Multi-Targeted Therapies – New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise
Published: July, 2012
Pages: 55
Price: US$ 3.500,00

The report provides an insight into different methods and techniques used to identify and design drugs that act upon multiple targets in the treatment of cancer. It also focuses on the design and development of combination therapies to address multiple targets in oncology and the challenges surrounding this. Pipeline analysis of the Phase III oncology pipeline focuses on indications such a lung cancer, breast cancer, colorectal cancer, prostate cancer, ovarian cancer, leukemia, lymphoma, head and neck cancer and multiple myeloma.The most common types of drug combinations used to treat these indications are highlighted and promising molecules in each indication have been identified.

More information can be found in the report “Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise” by GBI Research.

To order the report or ask for sample pages contact ps@marketpublishers.com

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com